Friday, 16 October 2026European Markets

ATOS Stock Was Up By 11.1% On Thursday

Loading stream...

(vianews) - the market ended the session with atos (ato.pa) rising 11.1% to €1.21 on thursday, after four successive sessions in a row of losses. cac 40 rose 0.42% to €8,040.12, following the last session's upward trend on what was a somewhat up trend exchanging session today.

about atos

atos se provides digital transformation solutions and services worldwide. it offers advanced computing solutions; analytics, artificial intelligence, and automation solutions; cloud solutions; customer journey analytics and digital customer experience; decarbonization solutions; digital consulting; digital workplace solutions; edge computing and internet of things solutions; and modern applications and platforms. the company also provides advance detection and response, data protection and governance, digital workplace security, iot and ot security, trusted digital identities, and cybersecurity solutions; and infrastructure and foundation services. it serves financial services and insurance, healthcare and life sciences, manufacturing, public sector and defense, resources and services, and telecommunication and media industries. the company was incorporated in 1982 and is headquartered in bezons, france.

earnings per share

as for profitability, atos has a trailing twelve months eps of €-31.04.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, atos's stock is considered to be overbought (>=80).

more news about atos (ato.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com